<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04011735</url>
  </required_header>
  <id_info>
    <org_study_id>1237-0097</org_study_id>
    <nct_id>NCT04011735</nct_id>
  </id_info>
  <brief_title>Re-usable Respimat® Soft MistTM Inhaler Study</brief_title>
  <official_title>A Real-world Non-interventional Study to Assess Patient Satisfaction With and Preference for Re-usable Respimat Soft Mist Inhaler in Patients With Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to assess patient satisfaction with the inhaler attributes of the re-usable
      Respimat SMI (Spiriva, Striverdi or Spiolto) in patients with COPD, including patients who
      are Respimat SMI-experienced and Respimat SMI-naïve. This study also aims to examine patient
      preference for the re-usable Respimat SMI compared to the disposable Respimat SMI in Respimat
      SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at
      study entry.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 30, 2019</start_date>
  <completion_date type="Actual">February 13, 2020</completion_date>
  <primary_completion_date type="Actual">February 13, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>mean total Patient Satisfaction and Preference Questionnaire (PASAPQ score)</measure>
    <time_frame>upto 6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total performance PASAPQ score for all patients at study end (follow-up assessment)</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total convenience PASAPQ score for all patients at study end (follow-up assessment)</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall satisfaction question with inhaler for all patients at study end (follow-up assessment)</measure>
    <time_frame>upto 6 weks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question on willingness to continue with inhaler for all patients at study end (follow-up assessment)</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Questions on ease of handling of the re-usable Respimat SMI for all patients at study end (follow-up assessment)</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in the mean total PASAPQ score between study entry (baseline visit) and study end (follow-up assessment) in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Question on preference for re-usable or disposable Respimat SMI at study end (follow-up assessment) in Respimat SMI-experienced patients switching from a disposable to a re-usable Respimat SMI product at study entry</measure>
    <time_frame>upto 6 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">262</enrollment>
  <condition>Pulmonary Disease, Chronic Obstructive</condition>
  <arm_group>
    <arm_group_label>Respimat SMI-experienced</arm_group_label>
    <description>patients who have been on maintenance treatment with a Respimat SMI product and receive a refill prescription at study entry</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Respimat SMI-naïve</arm_group_label>
    <description>patients who have not previously used a Respimat SMI product and receive their first prescription at study entry</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Respimat</intervention_name>
    <description>Soft Mist Inhaler product</description>
    <arm_group_label>Respimat SMI-experienced</arm_group_label>
    <arm_group_label>Respimat SMI-naïve</arm_group_label>
    <other_name>(Spiriva®, Striverdi® or</other_name>
    <other_name>Spiolto®)</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The study is planned that approximately with 250 Chronic Obstructive Pulmonary Disease
        (COPD) patients (Respimat SMI-experienced and Respimat SMI-naïve) from Europe will be
        enrolled in this study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Patients fulfilling all the following inclusion criteria will be eligible for participation
        in the study:

          -  Provision of signed informed consent prior to study data collection

          -  Patient with COPD aged 40 years or older

          -  Patient prescribed (or already receiving the disposable Respimat SMI and switched to)
             one of the following re-usable Respimat SMI products per the standard clinical
             practice: Spiriva 2.5 microgram inhalation solution; (2) Striverdi 2.5 microgram
             inhalation solution; and (3) Spiolto 2.5 microgram / 2.5 microgram inhalation solution

          -  Patient unlikely to change their Respimat therapy during the 4-6 week observation
             period (in the opinion of the investigator)

        Exclusion Criteria:

        Patients fulfilling any of the following exclusion criteria will not be eligible for
        participation in the study:

          -  Patient using a disposable Respimat SMI product during the study period

          -  Patient who have had a severe COPD exacerbation requiring hospitalisation in the
             immediate 3 months prior to study entry

          -  Patient participating in a clinical trial or any other non-interventional study of a
             drug or device at the time of enrolment

          -  Visual, cognitive, motor or health impairment that, as judged by the investigator, may
             cause concern regarding the patient's ability to complete the questionnaires

          -  Patient not fluent and literate in one of the main languages of the country
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Brussels - UNIV UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cliniques Universitaires de Bruxelles Hopital Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Notre-Dame de Grâce</name>
      <address>
        <city>Gosselies</city>
        <zip>6041</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Roeselare - HOSP AZ Delta</name>
      <address>
        <city>Menen</city>
        <zip>8930</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hvidovre Hospital</name>
      <address>
        <city>Hvidovre</city>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vejle Hospital</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porvoon sairaala</name>
      <address>
        <city>Porvoo</city>
        <zip>06150</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TYKS, Keuhkosairauksien klinikka, Turku</name>
      <address>
        <city>Turku</city>
        <zip>20520</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen, AöR</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MECS Research GmbH, Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>12203</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KPPK GmbH, Studienzentrum</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologiezentrum Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pneumologische Schwerpunktpraxis, 23558 Lübeck</name>
      <address>
        <city>Lübeck</city>
        <zip>23558</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amphia Ziekenhuis</name>
      <address>
        <city>Breda</city>
        <zip>4818 CK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisch Centrum Leeuwarden</name>
      <address>
        <city>Leeuwarden</city>
        <zip>8934 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Franciscus Gasthuis</name>
      <address>
        <city>Rotterdam</city>
        <zip>3045 PM</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gelre Ziekenhuis Zutphen</name>
      <address>
        <city>Zutphen</city>
        <zip>7207 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>M3 Helse AS Hamar</name>
      <address>
        <city>Elverum</city>
        <zip>N-2402</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hisøy Legesenter</name>
      <address>
        <city>Kolbjørnsvik</city>
        <zip>N-4816</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lambertseter Legesenter</name>
      <address>
        <city>Oslo</city>
        <zip>N-1157</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Svelvik Legesenter</name>
      <address>
        <city>Svelvik</city>
        <zip>N-3060</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Norway</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 4, 2019</study_first_submitted>
  <study_first_submitted_qc>July 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 8, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tiotropium Bromide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://trials.boehringer‐ingelheim.com/trial_results/ clinical_submission_documents.html to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.
Also, Researchers can use the following link http://trials.boehringeringelheim.com/ to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://trials.boehringer‐ingelheim.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

